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Abstract: The Breast Cancer Collaborative Registry (BCCR) is a multicenter web-based system that efficiently collects and manages 
a variety of data on breast cancer (BC) patients and BC survivors. This registry is designed as a multi-tier web application that utilizes 
Java Servlet/JSP   technology and has an Oracle 11g database as a back-end. The BCCR questionnaire has accommodated standards 
accepted in breast cancer research and healthcare. By harmonizing the controlled vocabulary with the NCI Thesaurus (NCIt) or System-
atized Nomenclature of Medicine-Clinical Terms (SNOMED-CT), the BCCR provides a standardized approach to data collection and 
reporting. The BCCR has been recently certified by the National Cancer Institute’s Center for Biomedical Informatics and Information 
Technology (NCI CBIIT) as a cancer Biomedical Informatics Grid (caBIG®) Bronze Compatible product.
The BCCR is aimed at facilitating rapid and uniform collection of critical information and biological samples to be used in developing 
diagnostic, prevention, treatment, and survivorship strategies against breast cancer. Currently, seven cancer institutions are participating 
in the BCCR that contains data on almost 900 subjects (BC patients and survivors, as well as individuals at high risk of getting BC).
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Introduction
Breast  cancer  (BC)  is  one  of  the  most  common 
  cancers  in  American  women,  with  over  192,000 
  estimated newly diagnosed cases of invasive BC and 
about 40,000 BC-related deaths in 2009.1 Incidence 
and mortality differ along racial lines.1
Small  BC  tumors  are  often  asymptomatic,  but 
larger tumors often present as a painless, palpable 
mass.1 Other, less common symptoms include breast 
pain and physical changes to the breast or nipple. The 
majority of patients with invasive BC are diagnosed 
at early stage disease, and only 6% of patients present 
with metastatic disease.2
Declines in BC incidence since the year 2000 are 
attributed to fewer women choosing hormone replace-
ment  therapy,3  as  recommended  by  the  Women’s 
Health Initiative,4 as well as decreased screening5 that 
would detect more, smaller cancers at an early stage. 
Invasive BC survival rates have shown improvement, 
with the 5-year survival rate at 89% and 15-year rate 
at 75%, however, these rates drop significantly with 
increasing stage or tumor size at diagnosis.1
Breast cancer survivors make up the largest diag-
nostic group among the 11.7 million Americans who 
are living after a diagnosis of cancer. Twenty-two per-
cent of all survivors, including 41% of all female sur-
vivors, have a history of BC.6 Despite the   prevalence, 
there  is  limited  information  about  the  long-term 
effects in BC survivors and the impact a diagnosis 
of BC had on the functioning and well-being of the 
  survivor’s family members. Individual patients differ 
in the importance they place on the risks and benefits 
of adjuvant therapy. Quality of life (QOL) needs to be 
evaluated to examine the impact of acute and long-
term side effects of adjuvant therapies.
Although  many  risk  factors  for  BC  have  been 
identified,  BC  etiology  remains  to  be  elucidated. 
Female  gender  and  increasing  age  are  the  two 
highest risk factors for BC. Hereditary factors, such 
as mutations in the BRCA1 and BRCA2 genes that 
account for 5% to 10% of BC cases,7–9 mutations in 
other common oncogenes such as TP53,10 CHEK2,11 
ATM,12 or PTEN,13 and family history play significant 
roles in a woman’s BC risk profile. It is well known 
that  some  BC  cases  exhibit  familial  clustering, 
however, the question of the extent of family history 
and genetic background toward BC initiation has been 
poorly studied. BRCA1/2 remain the most frequent 
genes of interest in BC genetics research. Studies on 
BRCA1/2 mutation carriers suggest that BRCA1/2’s 
influence on BC risk is modified by both non-genetic 
and genetic factors.14 Some carriers have little chance 
of a BC diagnosis, while others are diagnosed early 
into adulthood.7,15 Investigations of BC often focus on 
potential modifiers or regulators of BRCA1/2 or their 
downstream  targets  in  these  pathways.  Additional 
studies  are  needed  to  identify  other  oncogenes 
that are uniquely associated with BC initiation and 
progression. A woman’s personal history of BC is 
also a concern, with two to six times the risk of being 
diagnosed with a second primary cancer in the same or 
contralateral breast.16 Lifestyle factors such as having 
no children or having them later in age, as well as use 
of oral contraceptives, hormone replacement therapy, 
or alcohol, low or no amount of breastfeeding, and 
being overweight are all associated with the increased 
risk of BC development.1
Surveillance efforts and prospective identification 
of  at-risk  patients  are  useful  for  gathering  clinical 
data  and  biospecimens  that  can  be  used  toward 
the determination of BC risk factors, development 
of  the  comprehensive  prevention  strategies  and 
effective  treatment  regimens.  Registered  patients 
also  provide  a  wealth  of  potential  diagnostic  and 
prognostic information on environmental, nutritional, 
social, familial, and demographic factors in addition 
to clinical, biochemical, genetic, and epidemiological 
data. Most cases of BC are sporadic,17 and most of 
the aforementioned risk factors account for only a 
small portion of a patient’s risk profile. Due to the 
complexity of the disease, and the increasing evidence 
that  BC  itself  is  a  set  of  distinct  morbidities,18 
thorough  analysis  requires  detailed  data  sets  with 
large  sample  sizes  from  a  representative  patient 
population.  BC  is  characterized  by  high  incidence 
rates, but even the largest single-center studies lack 
the statistical power to study prospective factors that 
occur relatively infrequently within the BC patient 
subpopulation. Multi-center collaboration is required 
not only for sample size considerations, but to avoid 
regional effects specific to a local population, and for 
leveraging varying levels of expertise in the areas 
of  BC  epidemiology,  genetics,  biology,  pathology, 
early  detection  and  patient  care.  These  issues  can 
be  addressed  by  the  deployment  of  an  advanced 
information  technology  (IT)  infrastructure,  which Multicenter BCCR
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allows clinicians from various sites (centers) to input 
and analyze BC data in a standard, convenient, and 
secure  manner. A  foundation  of  standardized  data 
collection  and  patient  registration  is  essential  for 
building a system capable of advancing the field of BC 
research. Consistent, well-documented data models 
are required to develop databases and methodology 
capable of validation and analysis of BC clinical and 
biological data.
To  address  all  of  these  challenges,  the  Breast 
Cancer Collaborative Registry (BCCR) was devel-
oped and implemented as a web-based system at the 
UNMC Eppley Cancer Center (ECC). The BCCR is 
designed as a regional/national breast cancer resource 
that aims to facilitate rapid and uniform collection of 
critical information and biological samples to be used 
in developing new strategies for the prevention and 
treatment of breast cancer and improving QOL for 
BC survivors. The BCCR collects a variety of infor-
mation, including demographic, medical and family 
details, dietary and environmental exposure history, 
as well as biospecimen samples from breast cancer 
patients, women at increased risk for breast cancer 
(those with one or more first-degree relatives or at 
least two second-degree relatives with a history of 
cancer), and BC survivors.
This paper describes the biomedical informatics 
aspects of the BCCR development and organizational 
procedures that support BCCR activities.
Methods
The BCCR is a multi-tier web application that utilizes 
Java Servlet/JSP technology and has an Oracle 11g 
database  as  a  back-end.  The  Pancreatic  Cancer 
Collaborative  Registry  (PCCR)19  has  been  used 
as a foundation for the development of the BCCR. 
Adoption of the PCCR’s methodology allowed us to 
design the BCCR as a cancer Biomedical Informatics 
Grid  (caBIG®)  bronze  compatible  system.20  The 
caBIG®  is  a  voluntary  community  of  biomedical 
researchers  and  institutions  with  the  goals  being 
to:  connect  scientists  and  practitioners  through  a 
shareable  and  interoperable  infrastructure;  develop 
standard  rules  and  a  common  language  for  easily 
sharing  information;  and  build  or  adapt  tools  for 
collecting, analyzing, integrating, and disseminating 
information  associated  with  cancer  research  and 
care.21 The caBIG® compatibility guidelines22 specify 
the  compatibility  requirements  for  software  tools 
in  four  categories:  programming  and  messaging 
interfaces,  vocabularies,  common  data  elements, 
and  information  models.  The  BCCR  has  satisfied 
caBIG® bronze compatibility requirements in all four 
categories and has been certified by the NCI CBIIT as 
a caBIG® Bronze Compatible product.
Programming interface
BCCR end-users utilize a web interface for data entry 
and  management.  To  allow  third-party  applications 
to access the BCCR’s data directly and to satisfy the 
caBIG®  bronze  compatibility  requirements,  a  set  of 
application  programming  interfaces  (API)  has  been 
developed. This set of APIs consists of methods for both 
retrieving data from and inserting data into the BCCR.
Vocabulary
The  following  controlled  terminologies  have  been 
implemented both in the BCCR front-end and metadata: 
NCI Thesaurus (NCIt)23 and Systematized Nomencla-
ture of Medicine-Clinical Terms (SNOMED-CT).24 
These  publicly  accessible  controlled  vocabularies 
meet all caBIG® Bronze requirements.
data elements
The  Bronze  requirements  for  caBIG®  compatibility 
include “the availability of data element descriptions 
for every scientific data type that the system exposes”.22 
BCCR data element descriptors (metadata) have been 
constructed  from  the  aforementioned  vocabularies 
using  the  NCI  CBIIT  Data  Standards  Registry 
and  Repository  (caDSR)  common  data  elements 
convention25 and are available in an electronic format.
Information model
The  BCCR  data  is  stored  in  a  relational  database 
(Oracle 11g). All Protected Health Information (PHI) 
is  stored  encrypted  in  the  database  and  requires 
encryption/decryption functions with a pass phrase 
in order to insert or select data. A simplified entity-
relationship diagram (ERD) is presented in Figure 1.
organizational model
The BCCR utilizes the confederation model assuring 
that  each  institution  voluntarily  participates  in  the 
registry, retains all rights to its own data, and has equal 
representation in the registry’s steering committee. Sherman et al
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A  confederation  encourages  any  interested  center 
regardless  of  its  size  or  location  to  participate  in 
database  development  and  utilization.  The  data 
collected  at  any  location  can  be  used  by  other 
participants only after obtaining required permissions 
and  by  providing  corresponding  references  and 
acknowledgements.
Standardization
To satisfy the needs of different centers and create the 
foundation for future integration with other related 
data sources, we defined and established the criteria 
for standardization of collection forms and identified 
research questions that had to be addressed. All terms 
of  the  BCCR  controlled  vocabulary  are  explicitly 
numerated and described by an unambiguous defini-
tion drawn from the NCIt or SNOMED-CT. The data 
elements of the BCCR vocabulary have been defined 
based on the caDSR convention and, when possible, 
were mapped to the caDSR.
The BCCR questionnaires have been designed and 
developed to collect comprehensive data related to the 
diagnosis, treatment and follow-up of BC patients, as 
well as information pertaining to demographics and 
  survivorship. Existing, well established and   recognized 
in the cancer research community questionnaires, such 
as the SF-36v2 Health Survey to measure QOL26 and 
the NCI Quick Food Scan questionnaire27 for the dietary 
habits have been implemented in the BCCR registry. 
The American Cancer Society’s (ACS) examples of 
moderate versus vigorous physical activity guidelines 
for cancer prevention28 were used to create the physical 
activity form. Sleep habits are assessed by using the 
Pittsburgh Sleep Quality Index.29
According  to  the  BCCR  rules,  information  on 
personal,  demographic,  lifestyle,  physical  activity, 
dietary habits, family history, women’s health, genet-
ics data, symptoms, QOL, and medical history may 
be provided by a subject; whereas medical informa-
tion on diagnostic studies, pathology/staging, treat-
ment, surgeries, biospecimens, and survival can be 
provided only by clinical personnel. The Core Data 
Set categories included in this registry are described 
below.
Personal data collect patient identification infor-
mation  including  medical  record  number,  names, 
Figure 1. Simplified BCCR’s ERD.Multicenter BCCR
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date  of  birth,  and  contact  information. All  of  this 
information is stored encrypted in the database.
Demographic data capture the self-reported infor-
mation on race and ethnicity of the subject, their city/
state/country of birth, current marital status, income 
and education level, as well as religious preference. 
These data also include history of employment and 
toxic exposures.
Lifestyle data include information on tobacco usage 
as  well  as  alcohol,  coffee  and  caffeinated  beverage 
habits. For this purpose, the lifestyle page is designed 
with  descriptions  of  various  tobacco  and  alcohol 
products and drop-down boxes to enter the amount of 
each product used (e.g. the number of cigarettes per 
day). The age at which the subject started and stopped 
using each specific product is also captured in this data.
Physical  activity  data  include  current  physi-
cal activity levels and sleep habits. This page also 
prompts  subjects  to  recall  their  physical  activities 
over their lifetime. In order to do this, subjects are 
asked how active they were a year ago, at age 20, 
and, if applicable, at age 50. The page has descrip-
tions of various moderate and vigorous activities and 
drop-down boxes to enter the duration or time spent 
in the activity.
Dietary  habits  data  are  collected  based  on 
the  revised  edition  of  the  NCI  Quick  Food  Scan 
  questionnaire. Subjects are asked to complete a table 
regarding how often they ate certain fatty foods and if 
they feel their diet was high in fat, medium in fat, or 
low in fat. They are also asked if they have changed 
their eating habits since their BC diagnosis.
Family data provide information on the birth   status 
(e.g. a single birth, twin or one of a multiple birth), as 
well as ancestry. The subjects are asked to provide 
information on first and second degree relatives with 
the history of cancer and other major diseases.
Quality  of  life  (QOL)  questionnaire  utilizes  the 
SF-36v2  Health  Survey  that  measures  dimensions 
including  physical,  social/family,  emotional,  and 
functional well-being. Physical well-being addresses 
disease symptoms and side effects of therapy, while 
functional well-being applies to the patient’s ability 
to perform their role at work and home. Social or 
family  well-being  focuses  on  communication  with 
family members, the support and closeness they feel 
with their friends and family, and their satisfaction 
with their sex life. Emotional well-being includes a 
wide range of psychological impacts manifested by 
their  disease  and  therapy. The  additional  concerns 
address medical changes such as pain, shortness of 
breath, arm swelling, and change in weight as well as 
emotional changes regarding sexuality.
Medical history collects the subject’s self-reported 
history of their height/weight, performance of breast 
exams,  any  lifestyle  modifications  or  interventions 
they have employed, their menstruation history and 
reproductive history. Subjects are asked to address 
pre-existing or concurrent health problems and include 
the specific details of some of these problems.
Therapy history includes the self-reported history 
of the patient’s BC and the therapy received. Details of 
these received treatments are entered by the   clinician. 
Subjects are asked about follow-up care and moni-
toring, as well as about their use of complementary/
alternative therapies including: stress reduction tech-
niques, use of diet and nutritional supplements, and 
any traditional or ethnic remedies used.
Medical changes provide information on functional 
or medical changes after BC therapy. Details regarding 
any experience with lymphedema following surgery, 
as well as additional medical and functional changes 
concerning  urinary  difficulties,  hypothyroidism, 
cardiac problems, secondary cancers, and osteoporosis 
problems are addressed. Subjects are also asked if 
they have developed arthritis, scleroderma, or specific 
effects from radiation therapy. Endocrine symptoms 
are measured using the self-reporting FACT-ES scale,
30 
which is specific to endocrine/menopausal symptoms. 
Additional details regarding the subject’s experience 
with  hot  flashes,  and  infertility/reproductive  issues 
are also asked on this page. Fatigue is measured using 
the self-reporting FACIT-F scale.30 Questions include 
feelings regarding tiredness, weakness, and energy 
level, as well as cognitive issues that address their 
ability to start and finish things. Additional details 
regarding  the  subject’s  experiences  with  cognitive 
problems (mental or thought processes) are further 
addressed on this page.
Medical  data  are  entered  by  the  clinician  and 
include  listings  of  the  tests/procedures  completed 
at the time of diagnosis, including where and when 
the test was done. Biopsy and histology/pathology 
details, as well as the stage of disease at the time of 
diagnosis and the clinical stage of disease are entered. 
Details  regarding  the  affected  breast,  quadrant, Sherman et al
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surgical   margins, and lymph nodes or metastatic sites 
involved are included, as well as data on biochemical 
markers and details of hereditary breast cancer.
Treatment  data  include  details  regarding  dosage 
administration,  therapy  start  and  stop  dates,  best 
responses/outcomes,  and  schedules  of  any  hormonal 
therapy, immunotherapy, radiation therapy, chemotherapy, 
or any other therapies the subject has received.
Surgery  form  includes  details  regarding  the 
subject’s  mastectomy. The  outcome  of  the  surgery 
is evaluated by asking if there was a recurrence of 
disease,  the  site  of  recurrence  and  the  number  of 
months  to  the  first  recurrence.  Clinicians  are  also 
asked if there was any infection after surgery and if 
the subject had reconstructive surgery.
Follow-up  information  is  entered  by  a  clinician 
or  coordinator.  It  includes  data  on  the  disease’s 
progression or relapse, as well as any updates to the 
QOL, medical, treatment, and family history. The vital 
status of the subject is updated on this ‘Follow-up’ form 
including the date and cause of death if relevant.
Administrative data include: (i) date when ques-
tionnaire  is  submitted;  (ii)  current  status  of  the 
questionnaire;  (iii)  registering  institution  code; 
(iv)    clinician’s  ID;  and  (v)  subject’s  identification 
code—an   automatically generated number that can 
be used to re-identify the subject when data are de-
identified (as permitted by HIPAA regulations).
BCCR user interface
The BCCR public website (Fig. 2) can be accessed at 
http://bccr.unmc.edu/.
The BCCR user interface is compatible with all 
major  web  browsers,  such  as  Microsoft  Internet 
Explorer 6+, Mozilla Firefox 3+, Opera, and Safari. 
The  user  interface  and  data  collection  forms  were 
designed to eliminate ambiguity and to assist in accu-
racy and ease of data collection by providing pre-
defined selection of choices whenever possible. The 
BCCR system includes validation components that 
prevent entering erroneous information by the users. 
The  BCCR  developers  regularly  collect  feedback   
Figure 2. The BCCR website.Multicenter BCCR
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Figure 3. example of the BCCR user interface.
from the end users and evaluate the system’s interface 
for  further  improvements.  Figure  3  presents  an 
  example of the BCCR user interface.
To improve portability, convenience and ease of 
use, a separate interface for Apple’s iPads has been 
created. Initial testing has proved that the use of iPads 
helps subjects’ enrollment by creating a “cool factor” 
and removing a barrier between a patient and clinical 
personnel. Currently, about 97% of the approached 
subjects  have  been  signing  the  consent  forms  and 
about 63% of them filled out the questionnaires. Our 
preliminary data suggest that the use of Apple iPads 
as a mobile interface to the BCCR has increased the 
questionnaires’ return rate by ∼10%.
Integration with caTissue
The caTissue Suite,31 which is the tissue bank reposi-
tory tool developed under the caBIG® umbrella, has 
been adopted and integrated with the BCCR to collect 
and manage the biospecimen data in a standard and 
efficient way. It is used to track the collection, storage 
and  distribution  of  specimens  and  provides  quality 
assurance for all of these activities. The participating 
centers are able to either submit biospecimen data into 
the central repository or maintain their own installa-
tion of caTissue and store biospecimen data locally.
BCCR security
The  implementation  of  security  needs  reflects 
modern IT trends and ensures compliance with the 
electronic information  security standards  mandated 
by  the    Federal  Health  Insurance  Portability  and 
Accountability  Act  (HIPAA).  The  BCCR  protects 
the  patients’  personal  information  by  utilizing  the 
recommendations of the Healthcare Information and 
Management  Systems  Society  (HIMSS)  Privacy  & 
Security  Toolkit.32  The  BCCR  web  application  that 
supports data collection is accessible only for authorized 
users, and the patients’ PHI is stored encrypted. The 
system  utilizes  secure  web  server  communication 
and supports Secure Socket Layer (SSL) (an Internet 
encryption method that provides two-way encryption 
along the entire route that data travels to and from a 
user’s  computer)  and  Hypertext  Transfer  Protocol 
Secure (HTTPS) authentication (the communications 
standard used to securely transfer pages on the Web).
The authorized users must have their own unique 
electronic signature—a combination of a user name 
and a password. Each user has an appropriate level of 
access to data. The user roles and types of authority 
are described in Table 1.
IRB and subject recruitment
The BCCR participating centers are required to obtain 
approval from its Institutional Review Board (IRB). 
The  BCCR  provides  standard  protocol  templates 
and  privacy  assurances  in  procedures  of  informed 
consent that have been formulated to detail the use 
of web-based tools. A template of common protocol 
statements  includes:  (i)  methods  and  procedures Sherman et al
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applied  to  human  subjects;  (ii)  data  storage  and 
confidentiality;  (iii)  potential  risk  assessment  for 
human subjects; (iv) risk classification; (v) protection 
against  the  potential  risks  for  human  subjects; 
(vi) potential benefit assessment for human subjects; 
(vii) potential benefits to society; and (viii) alternatives 
to participation. A template for a common informed 
consent  form  includes  the  following  HIPAA-
mandated information: (i) a specific description of the 
information to be used or disclosed; (ii) the person 
or entity to whom disclosure will be made; (iii) the 
purpose of the use or disclosure; (iv) an expiration date 
or event for use of the information; (v) an explanation 
of how authorization may be revoked; and (vi) any 
restrictions  placed  on  the  subject’s  access  to  the 
information with access granted upon completion of 
the research. All participating investigators are able 
to use these standardized statements to assist them 
with their IRB applications.
All  BCCR  participating  researchers  and  clini-
cians are required to complete the computer-based 
training course on the Protection of Human Research 
Subjects.  All  information  gathered  in  the  BCCR 
should be compliant with IRB approvals at partici-
pating sites that are monitored by each center’s IRB. 
The  BCCR  coordinator  opens  new  accounts  and 
enables data entry into the BCCR only after receiv-
ing the documented proof of IRB protocol approval. 
In order to enter data into the BCCR, a copy of the 
consent form for each subject must be submitted to 
the BCCR coordinator. Under the informed consent 
process, study participants have been asked to vol-
untarily participate in the BCCR. The potential par-
ticipants are asked about their willingness to share 
the  information  they  provided  in  the  BCCR  with 
research   collaborators. The information the partici-
pants provide is collected for research purposes only. 
The subjects are informed in the consent that their 
PHI will be encrypted and that the web-based regis-
try is accessible to authorized users only. Identifiers 
will never be released in order to protect participant 
confidentiality. Every effort is made to ensure con-
fidentiality by means of data encryption, password 
authentication  of  users,  electronic  firewalls  and 
locked  storage  facilities,  de-identification  of  PHI, 
audit trails, a disaster prevention and recovery plan, 
and security measures for back-up.
Participants have also been informed that they may 
revoke the authorization to use and share their PHI at 
any time by contacting the principal investigator in 
writing. If they revoke the authorization, they may no 
longer participate in the research studies and the use 
or sharing of future PHI will be stopped, but the PHI 
which has already been collected may still be used.
data use agreements
To review and prioritize scientific projects, the BCCR 
Steering Committee has been formed to oversee all 
studies utilizing the BCCR data. The committee con-
sists of an appointed member from each participating 
institution and external advisors, including a patient 
advocate, and the BCCR coordinator.
Quality control
Quality of the collected data is ensured by the stan-
dardization of the collection forms that have been 
developed  with  predetermined  selection  choices 
to assist with the accuracy and ease of completion. 
Extensive  computer-based  procedures  assessing 
the accuracy of the submitted data and multi-layer 
control  (patient,  clinician,  center  manager,  system 
administrator) also ensure the quality and complete-
ness  of  gathered  information.  The  comprehensive 
training materials, manuals defining vocabulary used 
in the BCCR and user manuals with a defined set 
of procedures and lines of responsibilities for each 
level of participants were distributed to the centers. 
To guarantee the consistency and reliability of data 
Table 1. BCCR user roles and their authority.
Role Authority
Subject/patient Can enter/update personal, 
demographic, lifestyle, symptoms, 
QoL, family and medical history data
Lab technician Can enter/update biospecimen data 
only
Clinician All of the above + enter medical 
data, retrieve and edit existing cases 
of his/her patients
Coordinator All of the above for the assigned 
clinicians
Center manager All of the above + Retrieve and edit 




All of the above + Retrieve and edit 
all cases, activate/suspend users, 
assign user authoritiesMulticenter BCCR
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collection across the participating centers, the BCCR 
coordinator continuously provides educational train-
ing sessions and audits submitted data, whereas indi-
vidual  center  managers  review  the  data  submitted 
from their respective centers.
Results and Discussions
The  BCCR  was  initiated  as  the  Nebraska-based 
regional breast cancer data repository that has been 
evolved into a multicenter, multistate breast cancer 
collaborative registry. The BCCR is implemented as 
a bank of information with the ability to reference 
the institution and investigator where additional files/
samples are located. The BCCR maintains an audit 
trail  of  all  data  entries  to  protect  the  authenticity, 
integrity and confidentiality of all data entries. The 
collaborators  and  representatives  from  the  centers 
utilizing the BCCR system have developed organiza-
tional and operational procedures, standardized IRB 
applications and common consent forms, as well as 
bylaws for stockholders participating in multi-center 
collaborations.
At  the  present  time,  seven  cancer  centers  from 
three states participate in the BCCR: University of 
Nebraska Medical Center, Good Samaritan Hospital/
Cancer Center (Kearney, NE), St. Elizabeth’s Regional 
Medical Center (Lincoln, NE), Saint Francis   Medical 
Center/Cancer Treatment Center (Grand Island, NE), 
Penrose Cancer Center (Colorado Springs, CO), Holy-
oke Medical Center (Holyoke, MA), and St.   Vincent 
Hospital Center for Cancer Services (Worcester, MA). 
Data on 875 subjects are collected in the BCCR as of 
7/20/2011 (see Table 2).
Recently, the BCCR has been certified by the NCI 
Center for Biomedical Informatics and Information 
Technology as a caBIG® Bronze Compatible product. 
The BCCR serves as an effective medical informatics 
platform  for  the  successful  implementation  of 
collaborative  efforts  by  the  diverse  group  of 
researchers from multiple institutions with expertise 
in  oncology,  pathology,  epidemiology,  genetics, 
nutrition,  and  biomedical  computing.  The  BCCR 
development  and  utilization  provides  participating 
investigators with clear benefits of: (i) an effective 
and secure web-based system for standardized data 
collection; (ii) computerized data auditing and data 
quality control; (iii) ability to access larger data sets 
from  collaborating  centers  for  data  mining  and 
analysis; and (iv) enhanced collaboration with other 
breast cancer researchers and clinicians from different 
institutions.
In  the  near  future,  the  BCCR  will  be  virtually 
  integrated with other cancer- and health-related data-
bases developed at the UNMC Eppley Cancer Center, 
into a comprehensive cancer and health data resource 
equipped with an advanced data reporting and data 
mining system.
Acknowledgements
The development of the BCCR was partially   supported 
by  the  grant  from  the  National  Cancer  Institute 
(CA10595 “Expansion of Breast Cancer Resource of 
Eppley Cancer Center on NCCCP sites”, PI: Kenneth 
Cowan).
Disclosures
Author(s) have provided signed confirmations to the 
publisher of their compliance with all applicable legal 
and ethical obligations in respect to declaration of 
conflicts of interest, funding, authorship and contrib-
utorship, and compliance with ethical requirements 
in  respect  to  treatment  of  human  and  animal  test 
subjects. If this article contains identifiable human 
Table 2. BCCR enrollment.
number of subjects
By race
American Indian or Alaska native      4
Asian     5
Black or African American   50
Native hawaiian or other  
Pacific Islander
    1
White 779
Multiracial   10
Unknown/not reported   26
Total 875
By ethnicity










high-risk subjects   59
Total 875publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  yours!  you retain copyright
http://www.la-press.com
Sherman et al
226  Cancer Informatics 2011:10
subject(s) author(s) were required to supply signed 
patient consent prior to publication. Author(s) have 
confirmed that the published article is unique and not 
under consideration nor published by any other pub-
lication and that they have consent to reproduce any 
copyrighted material. The peer reviewers declared no 
conflicts of interest.
References
  1.  American  Cancer  Society.  Breast  Cancer  Facts  &  Figures  2009–2010. 
Atlanta: American Cancer Society; 2009. Available at: http://www.cancer.
org/Research/CancerFactsFigures/BreastCancerFactsFigures/f861009-
  final-9-08-09-pdf. Accessed April 26, 2011.
  2.  Ries LAG, Young JL, Keel GE, et al., editors. SEER Survival Monograph: 
Cancer Survival Among Adults: US SEER Program, 1988–2001, Patient 
and Tumor Characteristics. Bethesda, MD: National Cancer Institute; 2007. 
Available  at:  http://seer.cancer.gov/publications/survival/seer_survival_
mono_highres.pdf. Accessed September 29, 2010.
  3.  Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer 
incidence in 2003 in the United States. N Engl J Med. 2007;356:1670–4.
  4.  Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estro-
gen  plus  progestin  in  healthy  postmenopausal  women:  principal  results 
From  the Womens  Health  Initiative  randomized  controlled  trial. JAMA. 
2002;288:321–33.
  5.  Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates 
by age and tumor characteristics among US women. Breast Cancer Res. 
2007;9:R28.
  6.  Altekruse SF, Kosary CL, Krapcho M, et al., editors. SEER Cancer   Statistics 
Review,  1975–2007,  National  Cancer  Institute.  Bethesda,  MD,  2010. 
  Available at: http://seer.cancer.gov/csr/1975_2007/. Accessed April 26, 2011.
  7.  Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among 
BRCA1/2 carriers. JAMA. 2008;299:194–201.
  8.  King M-C. Breast and ovarian cancer risks due to inherited mutations in 
BRCA1 and BRCA2. Science. 2003;302:643–6.
  9.  National Cancer Institute. Genetics of Breast and Ovarian Cancer (PDQ). 
Genetics of Breast and Ovarian Cancer (PDQ). Available at: http://www. 
cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/Health-
Professional. Accessed April 21, 2010.
  10.  Garber JE, Goldstein AM, Kantor AF, et al. Follow-up study of twenty-four 
families with Li-Fraumeni syndrome. Cancer Res. 1991;51:6094–7.
  11.  Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance 
susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of 
BRCA1 or BRCA2 mutations. Nat Genet. 2002;31:55–9.
  12.  Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene. 
2006;25:5906–11.
  13.  Li J. PTEN, a putative protein tyrosine phosphatase gene mutated in human 
brain, breast, and prostate cancer. Science. 1997;275:1943–7.
  14.  Simchoni S. Familial clustering of site-specific cancer risks associated with 
BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. PNAS. 
2006;103:3770–4.
  15.  Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in 
BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum 
Genet. 1995;56:265–71.
  16.  Hankey  BF,  Curtis  RE,  Naughton  MD,  Boice  JD  Jr,  Flannery  JT. 
A   retrospective cohort analysis of second breast cancer risk for primary 
breast cancer patients with an assessment of the effect of radiation therapy. 
J Natl Cancer Inst. 1983;70:797–804.
  17.  Ritchie M, Hahn L, Roodi N, et al. Multifactor-Dimensionality Reduction 
Reveals  High-Order  Interactions  among  Estrogen-Metabolism  Genes  in 
Sporadic Breast Cancer. The American Journal of Human Genetics. 2001; 
69:138–47.
  18.  Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical 
outcome in breast cancer. Nat Med. 2008;14:518–27.
  19.  Sherman S, Shats O, Ketcham MA, Anderson MA, et al. PCCR: Pancreatic 
Cancer Collaborative Registry. Cancer Informatics. 2011;10:83–91.
  20.  caBIG Bronze Compatibility Certification. Bronze Compatible Products. 
Available  at:  https://cabig.nci.nih.gov/guidelines_documentation/bronze/. 
Accessed April 26, 2011.
  21.  caBIG Overview. Available at: https://cabig.nci.nih.gov/overview. Accessed 
April 26, 2011.
  22.  caBIG® Compatibility Guidelines. Available at: https://cabig.nci.nih.gov/
guidelines_documentation. Accessed April 26, 2011.
  23.  NCI Thesaurus. Available at: http://ncit.nci.nih.gov/ncitbrowser/. Accessed 
April 26, 2011.
  24.  Systematized Nomenclature of Medicine-Clinical Terms (SNOWMED-CT). 
International  Health  Terminology  Standards  Development  Organization, 
Available at: http://www.ihtsdo.org/snomed-ct. Accessed April 26, 2011.
  25.  NCI Data Standards Registry and Repository (caDSR). Available at: https://
cabig.nci.nih.gov/concepts/caDSR/. Accessed April 26, 2011.
  26.  Ware JE, Kosinski M, Dewey JE. How to Score Version Two of the SF-36 
Health Survey. Lincoln, RI: QualityMetric, Incorporated, 2000.
  27.  NCI Risk Factor Monitoring and Methods. Available at: http://riskfactor.
cancer.gov/diet/screeners/. Accessed April 26, 2011.
  28.  Kushi LH, Byers T, Doyle C, et al. American Cancer Society Guidelines on 
Nutrition and Physical Activity for Cancer Prevention: Reducing the Risk 
of Cancer With Healthy Food Choices and Physical Activity. CA Cancer 
J Clin. 2006;56:254–81.
  29.  Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh 
Sleep Quality Index (PSQI): A new instrument for psychiatric research and 
practice. Journal of Psychiatry Research. 1989;28:193–213.
  30.  Functional Assessment of Chronic Illness Therapy (FACIT). Available at: 
http://www.facit.org/FACITOrg/Questionnaires. Accessed April 26, 2011.
  31.  NCI caTissue Suite. Available at: https://cabig.nci.nih.gov/tools/  catissuesuite. 
Accessed April 26, 2011.
 32.  HIMSS Privacy and Security Toolkit. Available at: http://www.himss.org/ASP/
topics_privacySecurityToolkit.asp?faid=388&tid=4. Accessed April 26, 2010.